Spyre Therapeutics, Inc. (3920)
XDUS
Closed
Oct 7, 2026
Day's Range
70.0052 wk Range
13.50Overview - 3920 - Spyre Therapeutics, Inc.
Key Statistics
Valuation
P/E (Trailing)
‪-37.87‬
PEG Ratio
‪1.27‬
Price / Book
‪5.79‬
Profitability
Return on Assets
‪-19.95%‬
Return on Equity
‪-21.69%‬
Ownership
Shares Outstanding
88.06M
Price stats
50-Day Avg
‪82.80‬
200-Day Avg
‪57.36‬
Peers - 3920 - Spyre Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XDUS.
- 3920XDUSSpyre Therapeutics, Inc.+82.13%52-week change-37.88P/E (Trailing)—Profit Margin
- 0QFXDUSModerna Inc.+85.69%52-week change—P/E (Trailing)—Profit Margin
- 2LBXDUSIovance Biotherapeutics Inc.+83.47%52-week change-10.55P/E (Trailing)‪34.27%‬Profit Margin
- 0MEXDUSTwist Bioscience Corporation+80.08%52-week change-108.42P/E (Trailing)‪50.72%‬Profit Margin
- 42ZXDUSRevolution Medicines, Inc.+78.13%52-week change-30.44P/E (Trailing)—Profit Margin
- 3O8XDUSOmeros Corp.+77.85%52-week change-333.00P/E (Trailing)—Profit Margin
- 7BGXDUSOncoinvent ASA+76.57%52-week change-0.06P/E (Trailing)—Profit Margin
Profile Summary - 3920 - Spyre Therapeutics, Inc.
About
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing long-acting antibodies and antibody combinations for inflammatory bowel disease and other immune-mediated disorders. Spyre Therapeutics concentrates on advancing therapies designed to improve disease control, extend treatment…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
